Federation Des Caisses Desjardins Du Quebec Xilio Therapeutics, Inc. Transaction History
Federation Des Caisses Desjardins Du Quebec
- $23.7 Billion
- Q3 2025
A detailed history of Federation Des Caisses Desjardins Du Quebec transactions in Xilio Therapeutics, Inc. stock. As of the latest transaction made, Federation Des Caisses Desjardins Du Quebec holds 3,300 shares of XLO stock, worth $2,310. This represents 0.0% of its overall portfolio holdings.
Number of Shares
3,300
Previous 3,300
-0.0%
Holding current value
$2,310
Previous $2,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding XLO
# of Institutions
35Shares Held
11MCall Options Held
0Put Options Held
0-
Bain Capital Life Sciences Investors, LLC Boston, MA4.57MShares$3.2 Million1.25% of portfolio
-
River Vest Venture Management LLC St. Louis, MO1.44MShares$1.01 Million16.6% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.26MShares$878,9840.0% of portfolio
-
Morgan Stanley New York, NY962KShares$673,3410.0% of portfolio
-
Aju Ib Investment Co., Ltd. Seoul, M5668KShares$467,4190.49% of portfolio
About Xilio Therapeutics, Inc.
- Ticker XLO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 27,471,600
- Market Cap $19.2M
- Description
- Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. The company also develops cytokine prog...